1. Background
2. Objectives
3. Methods
3.1. Ethical Principles
3.2. Sampling
3.3. Study Data Extraction
3.4. Study Selection
3.5. Randomization of the Samples
3.6. Statistical Analysis
4. Results
4.1. Patient Characteristics
4.2. Evaluation of Biochemical Factors in the Subjects
| Variables | Milk Thistle | Statistical Test, P-Value | |||
|---|---|---|---|---|---|
| Before | Two Weeks | Four Weeks | One Month | ||
| AST (U/dL) | 0.001 | ||||
| Intervention group | 45.75 ± 13.2 | 42 ± 12.49 | 38.62 ± 12.41 | 37.87 ± 12.67 | |
| Control | 38.12 ± 8.17 | 40.84 ± 12.01 | 38.62 ± 7.39 | 39.12 ± 7.885 | |
| ALT (U/dL) | 0.001 | ||||
| Intervention group | 61.5 ± 21.81 | 55.75 ± 21.29 | 51.87 ± 21.68 | 51.12 ± 22.51 | |
| Control | 49.75 ± 7.86 | 49.12 ± 7.43 | 49.87 ± 7.31 | 50.87 ± 7.95 | |
| ALP (U/dL) | 0.001 | ||||
| Intervention group | 215.12 ± 38.57 | 203.25 ± 32.96 | 192.62 ± 31.44 | 191.12 ± 29.53 | |
| Control | 266.87 ± 103.82 | 265.25 ± 99.69 | 265 ± 98.61 | 270.35 ± 106.11 | |
| ALB (U/dL) | 0.001 | ||||
| Intervention group | 4.7 ± 0.34 | 4.56 ± 0.39 | 4.45 ± 0.37 | 4.49 ± 0.34 | |
| Control | 4.91 ± 0.18 | 4.97 ± 0.13 | 5.01 ± 0.14 | 4.96 ± 0.1. | |
| GGT (U/dL) | 0.001 | ||||
| Intervention group | 34.55 ± 27.78 | 28.7 ± 22.63 | 25.4 ± 19.32 | 24.65 ± 18.75 | |
| Control | 24.81 ± 9.15 | 26.63 ± 9.94 | 27.02 ± 9.25 | 27.45 ± 8.98 | |
| Bilirubin (mg/dL) | 0.001 | ||||
| Intervention group | 0.55 ± 0.26 | 0.45 ± 0.21 | 0.4 ± 0.17 | 0.37 ± 0.17 | |
| Control | 0.6 ± 0.14 | 0.6 ± 0.13 | 0.58 ± 0.13 | 0.61 ± 0.13 | |
| ESR (mm/hr) | 0.001 | ||||
| Intervention group | 9.25 ± 4.8 | 8.5 ± 3.61 | 7.5 ± 3.05 | 7.37 ± 2.82 | |
| Control | 9.5 ± 2.36 | 10.62 ± 1.45 | 11.5 ± 1.15 | 11.25 ± 1.98 | |
Abbreviations: AST, Aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ALB, albumin; GGT, gamma-glutamyl transpeptidase; ESR, erythrocyte sedimentation rate.
| Variables | Green Tea | Statistical Test, P-Value | |||
|---|---|---|---|---|---|
| Before | Two Weeks | Four Weeks | One Month | ||
| AST (U/dL) | 0.001 | ||||
| Intervention group | 41.87 ± 12.96 | 40.5 ± 12.84 | 38.87 ± 13.56 | 38.75 ± 13.92 | |
| Control | 38.12 ± 8.17 | 40.84 ± 12.01 | 38.62 ± 7.39 | 39.12 ± 7.885 | |
| ALT (U/dL) | 0.001 | ||||
| Intervention group | 53.12 ± 20.02 | 51.25 ± 19.76 | 49 ± 19.86 | 48.75 ± 20.05 | |
| Control | 49.75 ± 7.86 | 49.12 ± 7.43 | 49.87 ± 7.31 | 50.87 ± 7.95 | |
| ALP (U/dL) | 0.001 | ||||
| Intervention group | 273.37 ± 100.66 | 250.12 ± 85.06 | 241.5 ± 80.71 | 242 ± 80.54 | |
| Control | 266.87 ± 103.82 | 265.25 ± 99.69 | 265 ± 98.61 | 270.35 ± 106.11 | |
| ALB (U/dL) | 0.001 | ||||
| Intervention group | 4.91 ± 0.3 | 4.83 ± 0.33 | 4.73 ± 0.32 | 4.73 ± 0.32 | |
| Control | 4.91 ± 0.18 | 4.97 ± 0.13 | 5.01 ± 0.14 | 4.96 ± 0.1. | |
| GGT (U/dL) | 0.001 | ||||
| Intervention group | 46.03 ± 32.24 | 43.62 ± 29.78 | 41.08 ± 27.88 | 40.96 ± 27.60 | |
| Control | 24.81 ± 9.15 | 26.63 ± 9.94 | 27.02 ± 9.25 | 27.45 ± 8.98 | |
| Bilirubin (mg/dL) | 0.001 | ||||
| Intervention group | 0.57 ± 0.26 | 0.47 ± 0.23 | 0.45 ± 0.22 | 0.45 ± 0.22 | |
| Control | 0.6 ± 0.14 | 0.6 ± 0.13 | 0.58 ± 0.13 | 0.61 ± 0.13 | |
| ESR (mm/hr) | 0.001 | ||||
| Intervention group | 9.5 ± 4.5 | 8.75 ± 4.05 | 8.12 ± 3.7 | 7.87 ± 3.4 | |
| Control | 9.5 ± 2.36 | 10.62 ± 1.45 | 11.5 ± 1.15 | 11.25 ± 1.98 | |
Abbreviations: AST, Aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ALB, albumin; GGT, gamma-glutamyl transpeptidase; ESR, erythrocyte sedimentation rate.
| Variables | Cinnamon | Statistical Test, P-Value | |||
|---|---|---|---|---|---|
| Before | Two Weeks | Four Weeks | One Month | ||
| AST (U/dL) | 0.001 | ||||
| Intervention group | 44 ± 14.79 | 43 ± 14.34 | 42.12 ± 13.56 | 42.37 ± 13.26 | |
| Control | 38.12 ± 8.17 | 40.84 ± 12.01 | 38.62 ± 7.39 | 39.12 ± 7.885 | |
| ALT (U/dL) | 0.001 | ||||
| Intervention group | 51.12 ± 14.23 | 49.5 ± 14.48 | 48.25 ± 14.25 | 48.25 ± 13.75 | |
| Control | 49.75 ± 7.86 | 49.12 ± 7.43 | 49.87 ± 7.31 | 50.87 ± 7.95 | |
| ALP (U/dL) | 0.001 | ||||
| Intervention group | 231.25 ± 94.52 | 225.5 ± 92.19 | 220.37 ± 91.84 | 219.62 ± 91.35 | |
| Control | 266.87 ± 103.82 | 265.25 ± 99.69 | 265 ± 98.61 | 270.35 ± 106.11 | |
| ALB (U/dL) | 0.001 | ||||
| Intervention group | 5.01 ± 0.3 | 4.96 ± 0.25 | 4.91 ± 0.23 | 4.92 ± 0.26 | |
| Control | 4.91 ± 0.18 | 4.97 ± 0.13 | 5.01 ± 0.14 | 4.96 ± 0.1. | |
| GGT (U/dL) | 0.001 | ||||
| Intervention group | 21.23 ± 10.85 | 21.23 ± 10.85 | 20.58 ± 10.53 | 20.06 ± 10.44 | |
| Control | 24.81 ± 9.15 | 26.63 ± 9.94 | 27.02 ± 9.25 | 27.45 ± 8.98 | |
| Bilirubin (mg/dL) | 0.001 | ||||
| Intervention group | 0.57 ± 0.14 | 0.53 ± 0.15 | 0.52 ± 0.12 | 0.50 ± 0.13 | |
| Control | 0.6 ± 0.14 | 0.6 ± 0.13 | 0.58 ± 0.13 | 0.61 ± 0.13 | |
| ESR (mm/hr) | 0.001 | ||||
| Intervention group | 10 ± 5.26 | 9 ± 4.22 | 8.37 ± 3.61 | 7.87 ± 2.6 | |
| Control | 9.5 ± 2.36 | 10.62 ± 1.45 | 11.5 ± 1.15 | 11.25 ± 1.98 | |
Abbreviations: AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; ALP, Alkaline Phosphatase; ALB, albumin; GGT, Gamma-Glutamyl Trans peptidase; ESR, erythrocyte sedimentation rate.